Life Sciences & Pharma

Collaborative R&D to accelerate discovery and development through to clinical trial and into routine practice

“This project is based on collaborative relationships…We aren’t just asking for their data, we’re asking for their people.” Professor Craig Ritchie, Professor of the Psychiatry of Ageing, University of Edinburgh and European Prevention of Alzheimer’s Dementia co-ordinator

Collaborative business models require a new approach to infrastructure, security, and the sharing of information, processes and knowledge. Critical to the success of such a model is a strong information platform that promotes collaboration at both at the data and relationship levels in order to expedite the translation of research concepts into real-life diagnostic, pharmaceutical and biotech innovations.

AnalytiXagility is already facilitating the collaborative, reliable, and industrial implementation of cutting-edge informatics and analytics solutions for global life science and pharma companies including Janssen, Illumina, Novartis, Pfizer, Sanofi, Biogen, Philips Healthcare, Quintiles, ThermoFisher Scientific, Biogen, Fios Genomics, Amgen, Lilly, and Takeda, supporting their ambitions to take a leading role in healthcare transformation.

Closer collaboration powering innovation

Driven through Stratified Medicine Scotland’s Precision Medicine Ecosystem, AnalytiXagility brings life science and pharma companies closer to their collaboration partners to deliver an advantage in a high-cost, globally competitive environment. Enabling the integration of research expertise with real-world clinical, patient, imaging and genomic data to predict and validate the effects of new medical diagnostics and therapeutic interventions, AnalytiXagility provides a comprehensive picture of factors affecting each patient’s treatment and healthcare outcomes.

Contact us to discuss partnering for collaborative R&D and knowledge development